Brenig

Brenig Therapeutics is a neurology-focused small molecule drug development company that applies an AI/ML-based discovery platform — developed in partnership with Expert Systems Inc. — to identify and advance best-in-class therapies for neurodegenerative diseases. Its lead program, BT-267, is a brain-selective LRRK2 inhibitor designed for the treatment of idiopathic and LRRK2-mutated Parkinson's disease, with a pharmacokinetic profile optimized for high sustained brain exposure and minimal peripheral toxicity. A second asset, BT-409, is a brain-selective NLRP3 inhibitor that entered its first-in-human Phase 1 clinical trial in January 2026, initially in healthy volunteers. Brenig closed a $65 million Series A in July 2024 led by NEA, with participation from OrbiMed, Torrey Pines Investments, and BioGeneration Ventures. The company appointed David L. Lucchino as CEO and Tien Dam as Chief Medical Officer in 2025.